HER2 Antibody-TLR Agonist Conjugates for Localized Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments using TLR agonists often result in systemic cytokine release syndrome due to non-specific activation of immune responses, limiting their efficacy and tolerability.
Innovation Solution
Development of TLR-agonist conjugates (TCs) using non-naturally encoded amino acids for site-specific conjugation with targeting polypeptides, allowing localized immune stimulation at tumor sites while minimizing systemic effects, and optionally combined with chemotherapeutic or immunotherapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR agonists are administered systemically to stimulate immune responses, then immune activation is enhanced, but systemic cytokine release syndrome occurs
Solution Approach 1:
The patent applies local quality by conjugating TLR agonists to antibodies that specifically target tumor antigens, thereby localizing the immune-stimulating effect to tumor sites only. This spatial differentiation allows the TLR agonist to exert its immunostimulatory effect locally at the tumor while avoiding systemic distribution and the associated cytokine release syndrome.
Solution Approach 2:
The antibody serves as an intermediary carrier that bridges the TLR agonist to the tumor target. The antibody-TLR agonist conjugate allows the TLR agonist to be delivered specifically to tumor cells through antibody binding, mediating localized immune activation without direct systemic administration of the TLR agonist.
2Reliability
If TLR agonists are administered to treat cancer, then immune response is stimulated, but treatment tolerability is reduced due to systemic side effects
Solution Approach 1:
By confining the TLR agonist activity to the tumor microenvironment through antibody targeting, the treatment achieves effective local immune stimulation while minimizing systemic exposure. This localized action profile improves tolerability by reducing the incidence and severity of systemic adverse events such as cytokine release syndrome.
3Manufacturing precision
If non-naturally encoded amino acids are used for conjugation, then site-specific conjugation precision is improved, but manufacturing complexity increases
Solution Approach 1:
The patent changes the chemical parameter of the amino acid from natural to non-naturally encoded, introducing unique functional groups (such as azide, alkyne, or other reactive handles) that enable site-specific conjugation. This parameter change allows for precise control of conjugation location and stoichiometry, although it does require specialized manufacturing capabilities for incorporating non-canonical amino acids.
Data Source
AI summary
Disclosed herein are TLR-agonists and antibody-drug conjugates thereof. TLR agonist-antibody-drug conjugates of the disclosure comprise an antibody or an antibody fragment that can bind to HER2, and contain at least one non-natural amino acid. The TLR-agonist may be conjugated to a non-natural amino acid of the antibody via an oxime linkage. Further disclosed are methods for making and using such non-natural amino acid-containing TLR-agonists-antibody-drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.